Respiratory evaluation with FVC, FEV1 and DLCO was determined according to a joint statement based on the previous statements from the American Thoracic Society and European Respiratory Society [33] . Patients were evaluated the day of their discharge and every three months until six months all follow up were complete for each one. The concept was to evaluate whether these patients had clinical presentation of adverse effects of the virus on their respiratory capacity and to establish the duration of these effects.